CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 72 target
Drug / intervention
D-serine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00237848
NCT00237848Phase 3Completed
CompareCT.gov

D-Serine Augmentation of Cognitive Retraining in Schizophrenia

Yale University·interventional·Posted Oct 12, 2005·Updated Jun 18, 2012

In Brief

A Phase 3 clinical trial evaluating D-serine and Cognitive retraining for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 72 participants across 1 site.

Detailed Summary

This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesIndia
CollaboratorsStanley Medical Research Institute, Donaghue Foundation, US Department of Veterans Affairs, VA Office of Research and Development

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 12, 2005
Enrollment StartFeb 1, 2005
TodayJul 2, 2026
Posted 20.7 years ago

Interventions

D-serinedrug

Cognitive retrainingbehavioral